Neuronascent
Business Services · Maryland, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
6030 Daybreak Cir 244, Clarksville, Mary...Phone Number
(240) 876-7496Website
www.neuronascent.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Neuronascent
Neuronascent, Inc. specializes in neurogenesis and neuron regeneration, focusing on reversing neurological disorders such as Alzheimer's and Parkinson's diseases. The company is involved in drug discovery and has a robust pipeline of research and development programs. Their services are aimed at both human and veterinary medicine, targeting clients in need of innovative treatments for neurological conditions. Neuronascent is committed to advancing the understanding and treatment of neurological disorders through cutting-edge research.Explore more
Neuronascent Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neuronascent your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Neuronascent
Check out if Neuronascent is spiking on competitors!
Check if Neuronascent has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Neuronascent has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Neuronascent launches new products
Earning: See what the market has to say on Neuronascent recently announced quarterly report
Click to see if Neuronascent had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Neuronascent, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Neuronascent
Find 3 more new buyers
Compare Similar Companies to Neuronascent
Compare insights from companies similar to Neuronascent, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Neuronascent is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Neuronascent is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Neuronascent.
Neuronascent financials insights
Gather financial insights about Neuronascent, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$1.2M
Neuronascent Tech Stack
A closer look at the technologies used by Neuronascent
See more technologies
Neuronascent News & Media
Neuronascent Announces the Expansion of its Board of Directors | BioSpace
Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer Leahy, Ph.D., MBA, to its Board of Directors.Neuronascent Appoints Emer Leahy, Ph.D., MBA, To Board
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) — Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce... Read More The post Neuronascent Appoints Emer Leahy, Ph.D., MBA, To Board appeared first on citybiz.Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome
ROCKVILLE, Md., June 01, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc, today announced that the U.S. Food and Drug Administration (FDA) granted “Orphan Drug Designation” for the company’s NNI-351 treatment of Fragile X Syndrome.Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome
ROCKVILLE, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage biopharmaceutical company discovering and developing neuron-generating therapies for rare developmental disorders, today announced that the US Food and Drug Administration (FDA) granted rare pediatric designation for NNI-351 for Fragile X syndrome.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neuronascent
Sign Up For FreeTo access detailed company insights
Neuronascent, Inc. specializes in neurogenesis and neuron regeneration, focusing on reversing neurological disorders such as Alzheimer's and Parkinson's diseases. The company is involved in drug discovery and has a robust pipeline of research and development programs. Their services are aimed at both human and veterinary medicine, targeting clients... Read More
